# Breast Cancer

## Endocrine Therapy
- **ER/PR-POSITIVE HER2 NEGATIVE**
  - No Trial Currently Available
  - IRB#6256-ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular
- **HER2 POSITIVE**
  - No Trial Currently Available
- **“TRIPLE NEGATIVE” EP/PR-NEGATIVE HER2-NEGATIVE**
  - IRB#17461 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy
  - IRB#17504 MonarchE
  - IRB # 17887 SGN-L1V1A Part D
  - IRB # 17887 SGN-L1V1A Part E
  - S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
  - IRB#19200 Phase 3 DS-8201a; HER2-low Unresectable/Metastatic Breast Cancer
  - IRB#15366 Tucatinib beyond Pertuzumab and T-DM1
  - IRB 15588 SMMART

## Key
- Open for Enrollment
- In Development
- Enrollment on Hold

---

http://www.ohsu.edu/research/rda/so/knight.php

11/02/2018